Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05307731
PHASE4

Fingolimod for Type 2 Diabetes Mellitus

Sponsor: General Hospital of Shenyang Military Region

View on ClinicalTrials.gov

Summary

The aim of this study is to explore the efficacy and safety of Fingoland in the treatment of type 2 diabetes. A total of 40 patients were randomly divided into two groups. One group was treated with fingolimod, another group was given guideline based treatment. The changes of islet function in patients with glycosylated hemoglobin, insulin and C-peptide were observed .

Official title: Fingolimod for Type 2 Diabetes Mellitus: a Pilot, Prospective, Randomized, and Open Label Single-center Study

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2022-03-15

Completion Date

2026-03-15

Last Updated

2025-08-21

Healthy Volunteers

No

Interventions

DRUG

Fingolimod

0.5mg daily for 90-180 days, in addition to guideline-based treatment for DM

DRUG

guideline-based treatment for DM

guideline-based treatment for DM

Locations (1)

Department of Neurology, General Hospital of Northern Theater Command

Shenyang, China